17,207 research outputs found

    Metrics of the Gynecologic Oncology Literature Focused on Cited Utilization and Costs

    Get PDF
    OBJECTIVE: The newest findings on literature utilization relevant to gynecologic oncology were published by Thomson Reuters during June 2013 as determinants of journal standing. Our objective was to assess the different metrics reported for relative impact and cost for journals relevant to gynecologic oncology. METHODS: 55 journals were evaluated for Impact Factor (IF), 5Year IF, Immediacy Index, Cited Half Life, Eigenfactor (EF) Score, Article Influence (AI) scores and subscription costs obtained from publisher information. RESULTS: CA-A Cancer Journal for Clinicians had the highest IF (101.78) & AI (24.502). The top EF cancer-specific journals were the Journal of Clinical Oncology, Cancer Research, Clinical Cancer Research and Oncogene. Rankings for Gynecologic Oncology (409 articles, 18,243 citations) were IF=3.929, 43/55, EF=0.038, 28/55, and AI=1.099, 44/55, all higher than the previous year. The IF improved from the 5year IF in 31 journals, including Gynecologic Oncology, 29/31. Subscription costs for Gynecologic Oncology compared favorably to other journals. CONCLUSIONS: The high utilization of review information in CA-A Cancer Journal for Clinicians and Nature Review Cancer illustrated by the IF coupled with a relatively low number of articles and short cited half life indicates that they serve as a leading source of quoted cancer statistics (CA-A Cancer Journal for Clinicians). Rankings for Gynecologic Oncology and the International Journal of Gynecologic Cancer have improved. Regardless of specialty size, the Impact Factor for Gynecologic Oncology is respectably strong. The decreased IF in 44% of the journals may reflect the international economy\u27s effect on cancer research

    Responses of advanced directives by Jehovah\u27s Witnesses on a gynecologic oncology service

    Get PDF
    OBJECTIVES: To review the responses of advance directives signed by Jehovah\u27s Witness patients prior to undergoing surgery at a gynecologic oncology service. STUDY DESIGN: A retrospective chart review of gynecologic oncology patients undergoing surgery at a bloodless surgery center from 1998-2007 was conducted. Demographic, pathologic, and clinical data were recorded. The proportion of patients who accepted and refused various blood-derived products was determined and was compared to previously published results from a similar study of labor and delivery unit patients. RESULTS: No gynecologic oncology patients agreed to accept transfusions of whole blood, red cells, white cells, platelets, or plasma under any circumstance, whereas 9.8% of pregnant patients accepted transfusion (P=0.0385). However, 98% of gynecologic oncology patients agreed to accept some blood products, including fractions such as albumin, immunoglobulins, and clotting factors, while only 39% of pregnant patients agreed (

    Mechanisms and Novel Therapeutic Approaches for Gynecologic Cancer

    Get PDF
    This book—entitled “Mechanisms and Novel Therapeutic Approaches for Gynecologic Cancer”—was edited as a Special Issue of Biomedicines, focusing on basic research such as genomics, epigenomics, and proteomics, as well as clinical research in the field of gynecologic oncology. The number of patients with gynecological cancer has been increasing worldwide due to its high lethality and lack of early detection tools and effective therapeutic interventions. In this regard, basic research on its pathophysiology and novel molecular targeting intervention is required to improve the prognosis of gynecologic cancer. This book contains 13 papers, including 8 original research papers and 5 reviews focusing on the basic research of gynecologic oncology. The reader can learn about state-of-the-art research and obtain extensive knowledge of the current advances in the field of gynecologic oncology. It is my hope that this book contributes towards the progress of gynecologic oncology

    Perioperative Laboratory Abnormalities in Gynecologic Oncology Surgical Patients

    Full text link
    Background: Laboratory blood testing incurs financial costs and the blood draws can increase discomfort, yet minimal data exists regarding routine testing in gynecologic oncology surgical patients. Additionally, an increasing number of gynecologic oncology surgeries are performed via a laparoscopic approach. Thus, further investigation into perioperative laboratory testing for gynecologic oncology patients is warranted. An increasing number of gynecologic oncology surgeries are performed via a laparoscopic approach. Thus, further investigation into perioperative laboratory testing for gynecologic oncology patients is warranted. Objective: The aims of this study were (1) to evaluate the frequency and etiology of perioperative laboratory test abnormalities in patients undergoing laparoscopic and laparotomy surgery in a gynecologic oncology service, and (2) to establish an evidence-based algorithm to reduce unnecessary laboratory testing. Materials and Methods: A single-institution retrospective study was completed, investigating laparoscopic and laparotomic surgeries over 4 years. Information on preoperative and postoperative laboratory data, surgical parameters, perioperative interventions, and patient demographics was collected. Quality-assurance data were reviewed. Data were tabulated and analyzed using Statistical Product and Service Solutions (SPSS) version 22. A Student's t-test was used to test for group differences for continuous variables with equal variance, the Mann-Whitney?U test for continuous variables when unequal variance was detected, and Pearson's ?2 was used to investigate categorical variables of interest. p-Values 98% of patients underwent at least one preoperative and postoperative laboratory test, totaling 8060 preoperative and 5784 postoperative results. The laparoscopy group was significantly less likely to have postoperative metabolic abnormalities or to undergo perioperative blood transfusion. Patients taking an angiotensin-converting-enzyme inhibitor, angiotensin-II?receptor blocker, or diuretic were significantly more likely to have elevated creatinine preoperatively (odds ratio [OR]: 5.0; p?Peer Reviewedhttps://deepblue.lib.umich.edu/bitstream/2027.42/140101/1/gyn.2015.0106.pd

    Division of Gynecologic Oncology

    Get PDF
    The Division of Gynecologic Oncology at the University of Iowa provides comprehensive care for women with gynecologic malignancies. The Gynecologic Oncology Division is part of the Holden Comprehensive Cancer Center with clinical services located on the third floor of the Pomerantz Family Pavilion within the Women’s Health Clinic in the Department of Obstetrics and Gynecology. Our clinicians are highly experienced in robotic, laparoscopic, and open surgical procedures and base their approach on individual considerations for each case. As a long standing full member of the Gynecologic Oncology Group and a Phase I institution we actively participate in clinical trial enrollment, which includes in-depth knowledge of the design and implementation of clinical trials research. Additionally we have a strong basic science and translational research component

    Systemic Therapy in Endometrial Cancer: Recent Advances.

    Get PDF
    Endometrial cancer is a chemosensitive disease. Studies have established a clear benefit of chemotherapy in advanced stages and trials are ongoing to define its role in early stages as well. As more molecular pathways are being elucidated there is increasing role for targeted agents and future looks quite promising. We did an extensive search both online and offline for all the relevant articles including chemotherapy and targeted therapy for endometrial cancer

    Understanding the effect of stress hormones on ovarian cancer cells

    Get PDF
    Department of Cancer Systems Imaging Department of Gynecologic Oncology and Reproductive Medicinehttps://openworks.mdanderson.org/sumexp22/1022/thumbnail.jp
    • …
    corecore